NCT01143298已完成1 期
LEO 27847 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- PK parameters
研究概览
简要总结
The purpose of this phase 1 study is to determine the relative bioavailability following single oral dose administration of LEO 27847 solution compared to LEO 27847 tablets in healthy male subjects as well as to determine the effect of food on the single oral dose pharmacokinetics of LEO 27847 tablets in healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions.
- •Subjects will be Caucasian males between 18 and 45 years of age, with body mass index (BMI) between 18 and 32 kg/m2 inclusive.
- •Subjects will have a minimum weight of 50 kg
- •Subjects must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is acceptable)
排除标准
- •male subjects who are not willing to use appropriate contraception (such as condom) and for female partners; occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository) from the time of the first dose until 3 months after the final dosing occasion.
- •Subjects who have received any prescribed systemic or topical medication within 7 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety
- •Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety
- •Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety
- •Subjects who are still participating in a clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity), or a marketed drug within the past 3 months prior to the first dosing occasion.
- •Subjects who have donated any blood, plasma or platelets in the month prior to screening or who have made donations on more than two occasions within the 12 months preceding the first dose administration
- •Subjects with a significant history of drug allergy as determined by the Investigator
- •Subjects who have any clinically significant allergic disease (excluding non-active hay fever) as determined by the Investigator
- •Subjects who have a supine blood pressure and supine pulse rate at screening higher than 140/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50 mmHg and 45 bpm, respectively, confirmed by repeat
- •Subjects who consume more than 28 units of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse as determined by the Investigator
- •Subjects who smoke, or who have smoked within 3 months prior to first dose administration
- •Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, dermatological or other major disorders as determined by the Investigator
- •Subjects who have had a clinically significant illness within 4 weeks of the start of dose administration as determined by the Investigator
- •Subjects who are known to have hepatitis, or who are carriers of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or who have a positive result to the test for HIV
- •Subjects who, in the opinion of their General Practitioner (GP) or the Investigator, should not participate in the study, including subjects suspected for whatever reason of not being able to comply with the requirements of the protocol
研究组 & 干预措施
LEO 27847 oral solution 0.1 mg
Experimental
LEO 27847 oral solution 0.1 mg
干预措施: LEO 27847 oral solution (Drug)
LEO 27847 tablet 0.10 mg
Experimental
LEO 27847 tablet 0.10 mg
干预措施: LEO 27847 oral solution (Drug)
LEO 27847 tablet 0.01 mg
Experimental
LEO 27847 tablet 0.01 mg
干预措施: LEO 27847 oral solution (Drug)
结局指标
主要结局
PK parameters
时间窗: 7 weeks
AUC and Cmax in each group
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy SubjectsHealthyNCT01211964LEO Pharma15
已完成
1 期
Maribavir Food-Effect Study in Healthy Adults ParticipantsHealthy VolunteersNCT05382104Takeda31
已完成
1 期
A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male PatientsHealthy Male ParticipantsNCT01707342Janssen R&D Ireland6
已完成
1 期
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.BioequivalenceDiabetes Mellitus, Type 2NCT06124573Galenicum Health48
已完成
1 期
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.BioequivalenceDiabetes Mellitus, Type 2NCT06124547Galenicum Health48